Histone deacetylase inhibitors: The anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex)

Clinical and Experimental Metastasis

Volumn 25, Issue 7, 2008, Pages 703-716

  Tarasenko, Nataly ^a   Nudelman, Abraham ^b   Tarasenko, Igor ^a   Entin Meer, Michal ^c   Hass Kogan, Daphne ^c   Inbal, Aida ^a,d   Rephaeli, Ada ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d RABIN MEDICAL CENTER   (Israel)

Author keywords

4T1 Breast cancer; AN 7; AN 9; Angiogenesis; HDAC inhibition; HT 29; Lung metastases; Prodrugs; Prostate carcinoma

Indexed keywords

AN 7; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BUTYROYLOXYMETHYL DIETHYL PHOSPHATE; CARCINOEMBRYONIC ANTIGEN; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; PIVALOYLOXYMETHYL BUTYRATE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; COLON CARCINOMA; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MALE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TISSUE LEVEL; TISSUE SECTION; VASCULARIZATION; WESTERN BLOTTING; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BUTYRATES; BUTYRIC ACIDS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; NEOPLASM METASTASIS; ORGANOPHOSPHORUS COMPOUNDS; PTEN PHOSPHOHYDROLASE; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 53949087611     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-008-9179-x     Document Type: Article

References (40)

1. RR Rosato S Grant 2003 Histone deacetylase inhibitors in cancer therapy Cancer Biol Ther 2 30 37
2. Rephaeli A, Zhuk R, Nudelman A (2000) Prodrugs of butyric acid from the bench to bedside. Drug Dev Res 50:379-391. doi:10.1002/1098-2299(200007/08)50:3/ 4<379::AID-DDR20>3.0.CO;2-8
3. A Batova L Shao MB Diccianni 2002 The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines Blood 100 3319 3324 10.1182/blood-2002-02-0567
4. A Nudelman E Gnizi Y Katz 2001 Prodrugs of butyric acid (lll) novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases Eur J Med Chem 36 63 74 10.1016/S0223-5234(00)01199-5
5. A Nudelman I Levovich SM Cutts 2005 The role of intracellularly released formaldehyde and butyric acid, in the anticancer activity of acyloxyalkyl esters J Med Chem 48 1042 1054 10.1021/jm049428p
6. A Rephaeli M Entin-Meer D Angel 2006 The selectivity and anti-metastatic activity of oral bioavailable butyric acid prodrugs Invest New Drugs 24 383 392 10.1007/s10637-006-6213-1
7. D Engel A Nudelman I Levovich 2006 Mode of interaction between the HDAC inhibitor AN-7 and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines J Cancer Res Clin Oncol 132 673 683 10.1007/s00432-006-0116-6
8. SM Cutts A Nudelman V Pillay 2005 Formaldehyde-releasing prodrugs in combination with adriamycin can overcome cellular drug resistance Oncol Res 15 199 213
9. M Entin-Meer A Rephaeli X Yang 2005 Butyric acid prodrugs are histone deacetylase inhibitors that demonstrate anti-neoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas Mol Cancer Ther 4 1952 1961 10.1158/1535-7163.MCT-05-0087
10. M Entin-Meer X Yang SR Vandenberg 2007 In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas Neurooncology 9 82 88 10.1215/15228517-2006-032
11. A Rephaeli D Blank-Porat N Tarasenko 2005 In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer Int J Cancer 116 226 235 10.1002/ijc.21030
12. D Blank-Porat T Gruss-Fischer N Tarasenko 2007 The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties Cancer Lett 256 39 48 10.1016/j.canlet.2007.05.011
13. A Rephaeli S Waks-Yona A Nudelman 2007 Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicine-induced cardiotoxicity Br J Cancer 96 1667 1674 10.1038/sj.bjc.6603781
14. A Patnaik EK Rowinsky MA Villalona 2002 A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies Clin Cancer Res 8 2142 2148
15. T Reid F Valone W Lipera 2004 Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer Lung Cancer 45 381 386 10.1016/j.lungcan.2004.03.002
16. J Thompson F Grunert W Zimmermann 1991 Carcinoembryonic antigen gene family: molecular biology and clinical perspectives J Clin Lab Anal 5 344 366 10.1002/jcla.1860050510
17. BV Offersen M Borre FB Sørensen 2002 Comparison of methods of microvascular staining and quantification in prostate carcinoma: relevance to prognosis APMIS 110 177 185 10.1034/j.1600-0463.2002.100209.x
18. A Bikfalvi S Klein G Pintucci 1997 Biological roles fibroblast growth factor-2 Endocr Rev 18 26 45 10.1210/er.18.1.26
19. T Scholzen J Gerdes 2000 The Ki-67 protein: from the known and the unknown J Cell Physiol 182 311 322 10.1002/(SICI)1097-4652(200003)182:3<311:: AID-JCP1>3.0.CO;2-9
20. N Hosaka Y Ichikawa T Ishikawa 2001 Correlation of immunohistochemical p53 labeling index with inhibition rate in chemosensitivity test in gastric and colon cancer Anticancer Res 21 229 235
21. C Brahimi-Horn N Mazure J Pouysségur 2005 Signaling via the hypoxia-inducible factor-1 alpha requires multiple posttranslational modifications Cell Signal 17 1 9 10.1016/j.cellsig.2004.04.010
22. N Johansson M Ahonen M Kähäri 2000 Matrix metalloproteinases in tumor invasion CMLS (Cell Mol Life Sci) 57 5 15 10.1007/s000180050495
23. Y Tsuchiy H Sato Y Endo 1993 Tissue inhibitor of metalloproteinase-1 is a negative regulator of the metastatic ability of a human gastric cancer cell-line, Kkls, in the chic-embryo Cancer Res 53 1397 1402
24. M Watanabe Y Takahashi T Ohta 1996 Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase 1 gene in nude mice Cancer 77 1676 1680
25. MS Kim HJ Kwon YM Lee 2001 Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes Nat Med 7 437 443 10.1038/86507
26. A Chakravarti GG Zhai 2003 Molecular and genetic prognostic factors of prostate cancer World J Urol 21 265 274 10.1007/s00345-003-0362-z
27. DJ Mulholland S Dedhar H Wu 2006 PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer Oncogene 25 329 337 10.1038/sj.onc.1209020
28. I Vogel H Francksen E Soeth 2001 The carcinoembryonic antigen and its prognostic impact on immunocytologically detected intraperitoneal colorectal cancer cells Am J Surg 181 188 193 10.1016/S0002-9610(00)00555-9
29. T Liu S Kuljaca A Tee 2006 Histone deacetylase inhibitors: multifunctional anticancer agents Cancer Treat Rev 32 157 165 10.1016/j.ctrv.2005.12.006
30. H Sasano T Suzuki 2005 Pathological evaluation of angiogenesis in human tumor Biomed Pharmacother 59 S334 S336 10.1016/S0753-3322(05)80068-X
31. D Ribatti 2004 The involvement of endothelial progenitor cells in tumor angiogenesis J Cell Mol Med 8 294 300 10.1111/j.1582-4934.2004.tb00319.x
32. M Presta P Dell'Era S Mitola 2005 Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis Cytokine Growth Factor Rev 16 159 178 10.1016/j.cytogfr.2005.01.004
33. B Nicholson D Theodorescu 2004 Angiogenesis and prostate cancer tumor growth J Cell Biochem 91 125 150 10.1002/jcb.10772
34. D Ribatti G Surico A Vacca 2001 Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma Life Sci 68 1161 1168 10.1016/S0024-3205(00)01030-4
35. ZS Zhao JL Zhou GY Yao 2005 Correlative studies on bFGF mRNA and MMP-9 mRNA expressions with microvascular density, progression, and prognosis of gastric carcinomas World J Gastroenterol 11 3227 3233
36. BK Jee KM Park S Surendran 2006 KAI1/CD82 suppresses tumor invasion by MMP9 inactivation via TIMP1 up-regulation in the H1299 human lung carcinoma cell line Biochem Biophys Res Commun 342 655 661 10.1016/j.bbrc.2006.01.153
37. EJ Yeo YS Chun JW Park 2004 New anticancer strategies targeting HIF-1 Biochem Pharmacol 68 1061 1069 10.1016/j.bcp.2004.02.040
38. HE Ryan M Poloni W McNulty 2000 Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth Cancer Res 60 15 4010 4015
39. MD Sadar ME Gleave 2000 Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells Cancer Res 60 5825 5830
40. K Abrahamsson BO Eriksson E Holme 1996 Pivalic acid-induced carnitine deficiency and physical exercise in humans Metabolism 45 1501 1507 10.1016/S0026-0495(96)90179-1